Get the Stockscreener App
12.88
1.02%
0.13
After Hours:
12.88
Bioage Labs Inc stock is traded at $12.88, with a volume of 327.65K.
It is up +1.02% in the last 24 hours and up +60.80% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$12.75
Open:
$12.72
24h Volume:
327.65K
Relative Volume:
0.83
Market Cap:
$461.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+10.94%
1M Performance:
+60.80%
6M Performance:
+186.86%
1Y Performance:
+180.61%
1-Day Range:
$12.55
$13.06
1-Week Range:
$11.05
$13.10
52-Week Range:
$2.88
$13.10
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
12.88 | 457.15M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-22-25 | Upgrade | Citigroup | Neutral → Buy |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
Morgan Stanley Upgrades BioAge Labs (BIOA) - Nasdaq
BioAge Labs (BIOA) Competitors and Alternatives 2025 - MarketBeat
Volume Recap: How BioAge Labs Inc stock reacts to Fed rate cutsFed Meeting & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
BioAge Labs CMO Paul D. Rubin Sells All Common Stock Holdings - TradingView
Officer Rubin Sells 68,897 ($701.9K) Of BioAge Labs Inc [BIOA] - TradingView
BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data - Investing.com South Africa
How BioAge Labs Inc. stock reacts to Fed rate cutsShort Setup & Fast Gain Stock Trading Tips - Newser
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial - Investing.com Nigeria
Is BioAge Labs Inc. stock a safe haven assetQuarterly Earnings Summary & Safe Entry Zone Identification - Newser
Why BioAge Labs Inc. stock remains undervaluedCEO Change & Smart Money Movement Alerts - Newser
How BioAge Labs Inc. (Y7G) stock stacks up against competitorsInsider Selling & Daily Chart Pattern Signal Reports - Newser
Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs - TipRanks
Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Officer Rubin Files To Sell 68,897 Of BioAge Labs Inc [BIOA] - TradingView
Will BioAge Labs Inc. (Y7G) stock outperform global peersCEO Change & Safe Capital Investment Plans - Newser
Merger Talk: Is BioAge Labs Inc stock a safe haven assetPortfolio Growth Summary & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues - marketscreener.com
BioAge Reports Positive Interim Phase 1 Data For BGE-102; Shares Rise - Nasdaq
BioAge Labs Announces Positive Phase 1 Trial Results - TipRanks
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - markets.businessinsider.com
BioAge Labs, Inc. Announces Positive Interim Phase 1 Data for BGE-102 - TradingView
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial By Investing.com - Investing.com South Africa
Is BioAge Labs Inc. (Y7G) stock a buy before new product rolloutJuly 2025 Outlook & Long Hold Capital Preservation Plans - Newser
Is BioAge Labs Inc. (Y7G) stock bottoming after sell off2025 Major Catalysts & Daily Volume Surge Trade Alerts - Newser
BioAge Labs announces positive phase 1 trial results - MSN
Bioage Labs (BIOA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is BioAge Labs Inc. (Y7G) stock supported by free cash flowVolume Spike & Fast Moving Stock Watchlists - Newser
Jefferies Financial Group Inc. Buys Shares of 50,000 BioAge Labs, Inc. $BIOA - MarketBeat
What analysts say about BioAge Labs Inc Y7G stockFibonacci Extensions & Rapid Capital Trading Tips - earlytimes.in
Dhanalaxmi Roto Spinners Limited Stock Analysis Technical Signals for YEARCash Flow Trends & Invest With Confidence - earlytimes.in
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - Sahm
Recent uptick might appease BioAge Labs, Inc. (NASDAQ:BIOA) institutional owners after losing 55% over the past year - Yahoo Finance
Is BioAge Labs Inc a good long term investmentCapital Gains Strategies & Small Budget Portfolio Growth - earlytimes.in
BioAge stock craters 70% on obesity drug study halt (update) - MSN
Is BioAge Labs Inc. stock recession proofStop Loss & Free Weekly Watchlist of Top Performers - newser.com
Will BioAge Labs Inc. (Y7G) stock hit analyst forecastsBuy Signal & Expert Curated Trade Ideas - newser.com
BioAge Labs (BIOA) Price Target Increased by 20.83% to 9.86 - MSN
Is BioAge Labs Inc. (Y7G) stock a buy on weakness2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
How interest rate cuts could boost BioAge Labs Inc. stock2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Is BioAge Labs Inc. stock a buy before product launchesMarket Volume Report & Weekly Top Stock Performers List - newser.com
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bioage Labs Inc Stock (BIOA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Dec 09 '25 |
Sale |
12.00 |
18,000 |
216,000 |
0 |
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):